3-FPM (3-Fluorophenmetrazine): Complete Human Toxicology, Pharmacokinetics & Dependence Monograph

3-FPM (3-Fluorophenmetrazine): Complete Human Toxicology, Pharmacokinetics & Dependence Monograph

Emergency stimulant toxicity: Severe agitation/confusion, seizure, chest pain, dangerous overheating, collapse, severe shortness of breath, loss of consciousness, or a cold/painful/pale limb after an unknown stimulant can represent a medical emergency.

Quick answer

3-FPM is 3-fluorophenmetrazine, a fluorinated analogue of the former prescription stimulant phenmetrazine.

Compared with many research-chemical stimulants, it has an unusually diverse evidence base:

• 19 analytically confirmed hospitalized patients in the Swedish STRIDA project;
• direct monoamine-transporter pharmacology;
• human urine/CYP metabolism;
• a controlled single-person PK study;
• severe vascular/kidney injury;
• mixed overdose reports;
• fatal polysubstance cases;
• postmortem tissue-distribution data.

The major evidence gap is not whether 3-FPM is pharmacologically active or potentially dangerous.

It is the absence of large controlled human dose-response and dependence studies.

Identity

History

3-FPM is structurally related to phenmetrazine, a stimulant/anorectic once used medically and later controlled because of abuse potential.

3-FPM was patented in 2011 and appeared on recreational drug markets by 2014.

It was sold online as a research chemical in:

• powders;
• colored pellets/tablets.

By 2014–2015, Swedish poison-center and STRIDA surveillance was already documenting hospital presentations.

Relationship to phenmetrazine

Phenmetrazine is internationally controlled in Schedule II of the 1971 Convention and has well-established stimulant abuse liability.

Adding a fluorine at the 3-position creates 3-FPM.

That modification does not preserve a simple clinical potency or dose ratio.

3-FPM requires its own:

• pharmacokinetic;
• toxicological;
• forensic

evidence.

Pharmacology

Direct transporter work shows fluorinated phenmetrazines behave as substrates of high-affinity monoamine transporters.

3-FPM primarily increases signaling through:

• dopamine;
• norepinephrine;

with comparatively less serotonergic emphasis.

WHO summarizes it as a potent dopamine/norepinephrine releaser with effects resembling amphetamine-type stimulants.

Expected stimulant effects

Human effects reported in surveillance/review data include:

• euphoria;
• stimulation;
• increased energy;
• talkativeness;
• insomnia.

Adverse effects include:

• tachycardia;
• agitation;
• delirium;
• seizures.

Mechanistic similarity does not make 3-FPM interchangeable with amphetamine or phenmetrazine.

STRIDA: 19 analytically confirmed patients

From November 2014 through October 2015, Swedish STRIDA testing confirmed 3-FPM in 19 patients.

Patients were mostly men, aged 22–54 years.

Serum concentrations among positive serum specimens ranged from:

• 2.7 to 1,416 ng/mL.

Urine concentrations also spanned a very wide range.

Why this series matters

It establishes real hospital-treated exposure, not just internet reports or seized powder.

Why it is still confounded

Many patients also had other psychoactive substances present.

Therefore a concentration cannot be converted directly into:

• symptom severity;
• dose;
• impairment.

Acute toxicity

Reported severe effects include:

• tachycardia;
• hypertension;
• agitation;
• anxiety;
• delirium;
• seizures;
• altered consciousness.

Repeated exposure can also contribute to:

• insomnia;
• psychiatric destabilization;
• dehydration;
• cardiovascular stress.

Critical limb ischemia and acute kidney injury

One of the most striking 3-FPM reports involved intravenous administration.

The person developed:

• malaise;
• tachycardia soon after exposure;
• later severe acute kidney injury;
• irreversible ischemia affecting all four limbs.

The case demonstrates the possibility of catastrophic vascular injury in an extreme exposure context.

Evidence boundary

This does not establish the incidence of limb ischemia in typical oral or other recreational exposure.

Route, amount, contamination and individual factors all matter.

Vasoconstriction and vascular risk

Powerful catecholaminergic stimulation can produce:

• peripheral vasoconstriction;
• hypertension;
• impaired tissue perfusion.

Cold, painful, pale, blue or numb extremities—especially if persistent—warrant urgent medical assessment.

Mixed overdose with etizolam

A 33-year-old man presented unconscious after co-exposure to:

• 3-FPM;
• etizolam.

This illustrates how a stimulant + sedative mixture can produce a clinical picture very different from simple stimulant excitation.

Product or intentional polysubstance use can mask warning symptoms.

Fatality evidence

3-FPM + U-47700

A published forensic case involved 3-FPM and the potent synthetic opioid U-47700.

The death was a multiple-drug toxicity.

This is not evidence for a 3-FPM-only fatal level.

Designer benzodiazepines + stimulants

Another postmortem case contained:

• 3-FPM;
• pyrazolam;
• diclazepam and metabolites;
• 2-FA;
• evidence of 2-FMA;
• methiopropamine;
• amphetamine.

Cause of death involved positional asphyxia promoted by polydrug intoxication.

Again, 3-FPM detection is not sole causation.

Postmortem distribution

In the organ-distribution case, 3-FPM was measured in:

• femoral blood;
• tissue;
• bile.

The authors did not find evidence suggesting substantial postmortem redistribution for 3-FPM in that case.

One case cannot establish a universal redistribution profile.

Human pharmacokinetics

A 2019 study used a controlled self-experiment to generate preliminary human PK information.

Reported values included:

• serum peak around 2.5 hours;
• peak serum concentration around 210 ng/mL;
• estimated elimination half-life around 8.8 hours;
• large apparent volume of distribution.

3-FPM remained detectable much longer than the obvious peak period in:

• serum;
• urine;
• oral fluid.

Why the PK numbers require a warning

The experiment involved one volunteer.

It does not establish:

• population variability;
• safety in repeated use;
• interactions;
• accumulation;
• impairment duration.

An 8.8-hour estimate is not a redosing, driving or “time until sober” formula.

Metabolism

Human/rat metabolism studies show 3-FPM is excreted substantially as unchanged parent drug.

Major pathways include:

• aryl hydroxylation;
• N-hydroxylation;
• oxidative morpholine-ring opening.

An oxidative ring-opening product had a particularly long analytical detection window in the controlled self-experiment.

CYP involvement

Researchers examined human cytochrome P450 isoenzymes involved in phase-I metabolism.

These data improve understanding of:

• interindividual variability;
• possible drug interactions;
• metabolite selection.

A complete controlled interaction map does not exist.

Drug testing

Routine screens

3-FPM may be absent from standard hospital/workplace panels.

A generic amphetamine screen does not reliably identify 3-FPM as the specific compound.

Definitive testing

Published methods use:

• LC-MS/MS;
• LC-HRMS;
• GC-MS;
• parent + metabolite targets.

2-FPM / 3-FPM / 4-FPM isomer distinction

A 2017 analytical study purchased material from five online vendors and developed methods distinguishing:

• 2-FPM;
• 3-FPM;
• 4-FPM.

All five tested vendor samples were consistent with 3-FPM.

The broader lesson is that fluorine position is an analytical identity question, not something a seller name proves.

Interactions

No controlled 3-FPM interaction trials define safe combinations.

Important concerns include:

• other stimulants → greater cardiovascular/vascular stress;
• MAO inhibitors → potentially dangerous monoaminergic amplification;
• alcohol/benzodiazepines → impaired judgment and mixed intoxication;
• opioids → respiratory depression from the opioid component.

The fatal U-47700 case demonstrates the opioid-stimulant combination in real forensic practice.

Tolerance

Repeated stimulant exposure can produce tolerance to some subjective effects.

No validated 3-FPM-specific tolerance timeline exists.

Diminished stimulation does not prove protection from:

• hypertension;
• vasoconstriction;
• seizure;
• psychiatric toxicity;
• sleep deprivation.

Dependence and stimulant use disorder

WHO considered 3-FPM's mechanism and effects sufficiently similar to phenmetrazine/amphetamine-type stimulants to recognize abuse/dependence concern.

Direct epidemiologic estimates are limited.

Potential warning signs include:

• craving;
• repeated redosing;
• inability to cut down;
• binge patterns;
• continued use despite cardiovascular, psychiatric or functional harm.

Stimulant withdrawal

After sustained stimulant use, withdrawal can involve:

• profound fatigue;
• hypersomnia or insomnia;
• depressed mood;
• anhedonia;
• irritability;
• slowed thinking;
• increased appetite;
• craving.

No validated 3-FPM-specific withdrawal onset/peak/duration is available.

Severe depression, suicidality or persistent psychosis warrants urgent evaluation.

Treatment and support

There is no medication approved specifically for 3-FPM use disorder.

The ASAM/AAAP stimulant-use-disorder guideline identifies contingency management as a core evidence-based behavioral treatment, often combined with CBT/community reinforcement.

Acute poisoning is managed according to actual complications.

U.S. resources include:

• FindTreatment.gov
• SAMHSA National Helpline: 1-800-662-HELP (4357)

Forensic interpretation

Blood concentration is not dose

The STRIDA serum range was enormous.

Timing, tolerance, route and co-drugs matter.

Fatal cases are polysubstance

Published fatalities do not define a 3-FPM-only lethal concentration.

PK detectability is not impairment

Drug detection for days does not mean equivalent impairment persists for days.

Special populations

Controlled 3-FPM safety data are inadequate for:

• pregnancy/breastfeeding;
• adolescents;
• older adults;
• cardiovascular/vascular disease;
• kidney disease;
• seizure disorders;
• serious psychiatric illness.

The limb-ischemia/AKI case makes vascular and renal vulnerability especially important to keep visible.

Legal and regulatory status — dated October 3, 2026

WHO / international

WHO critically reviewed 3-FPM at its 43rd ECDD in 2020.

The Committee recommended surveillance, not international scheduling.

WHO's updated surveillance list continued to list 3-FPM under surveillance in 2025.

UNODC identifies it as a phenmetrazine stimulant NPS.

Therefore 3-FPM is not under international convention control as of the evidence reviewed here.

United States

A 2020 U.S. federal notice stated that 3-FPM was not a controlled substance under the CSA.

This review did not identify a later specific DEA scheduling action naming 3-FPM by October 3, 2026.

State law and federal analogue-law questions can still differ depending on facts and jurisdiction.

Myths and misconceptions

“3-FPM is just a mild research stimulant.”
False. Hospital-treated poisonings, seizures and catastrophic vascular injury are documented.

“The 8.8-hour half-life tells everyone when they are safe to redose or drive.”
False. It came from one volunteer.

“A high STRIDA serum level automatically means worse poisoning.”
No. Concentrations and clinical severity are confounded by timing and co-drugs.

“The U-47700 death proves a 3-FPM lethal concentration.”
False. It was a multiple-drug toxicity.

“Not internationally scheduled means WHO considers it safe.”
False. WHO explicitly keeps it under surveillance because of public-health concern.

Evidence ledger

Related evidence

• Non-cathinone RC stimulants
• N-Ethylhexedrone
• α-PiHP
• 2-MMC
• Synthetic cathinones & RC stimulants
• Substance Use, Dependence & Harm Reduction hub

Bottom line

3-FPM is one of the better-characterized non-cathinone research stimulants.

Its evidence base includes hospital case series, human metabolism, direct monoamine-transporter pharmacology, a preliminary human PK study, catastrophic vascular injury, and multiple fatal polysubstance investigations.

That evidence supports taking it seriously while resisting false precision.

The responsible summary is:

real stimulant toxicity, real abuse potential, real vascular risk—and still no validated safe dose, lethal threshold or universal duration timer.